InvestSMART

Dianthus Therapeutics (NASDAQ: DNTH) - Share Price

Current share price for DNTH : $110.070 1.03 (0.93%)+

Currency: USD ($)

Dianthus Therapeutics Inc. is a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients with severe autoimmune diseases. The company operates as a single segment and has one reportable segment, focusing on creating next-generation treatments to revolutionize the management of severe autoimmune conditions. The team comprises experienced biotech and pharma executives. The pipeline includes the potential of Claseprubart, a next-generation complement therapeutic.

DNTH General Information +

NASDAQ Code DNTH
Industry/Sector Biotechnology
Market Cap ($M) 6,017
DNTH Share Price $110.070
Day High $111.000
Day Low $108.500
Last Close $111.100
DNTH Share Price Movement $1.03 ( 0.93% )
Prices as at 3:44, 25 Aug 2026
+Security prices are at best end-of-day and are indicative only.

DNTH Financial Summary

Operating Revenue Per Share Price to Operating revenue Price to free cash flow Earnings Yield PE Ratio Dividend Yield Forward Dividend Yield Forward Earnings Yield
$0.11 $959.44 ($33.04) 30.88% 3.24 n/a n/a -3.48

DNTH Calendar of Events

Created Date Changed Date Event
10 April 2026 10 April 2026 Company Meeting

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.